Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourExpanding
15 minLeaning Bullish
5 minConsolidating
Daily trend turns up above $16.94
Key levels
Resistance$2.13
Resistance$1.80
Support$1.27
Latest news & SEC filings
EarningsCervoMed Inc. Posts Third-Quarter 2026 Results, Updates Cash Position
All CRVO news →CervoMed is a biotech firm in the clinical testing phase that works on therapies for brain conditions tied to aging. Its main candidate, neflamapimod, is taken by mouth and blocks the p38α enzyme, and it is being tested in patients with dementia with Lewy bodies, a form of progressive aphasia, ischemic stroke recovery, and ALS. The company is based in the United States and runs trials across North America and Europe.
Based on the company's 10-K filed Mar 13, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CRVO.
Start Free Trial →Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
12
Moat Score
NONE
1/9
Piotroski Score
-7.3
Altman Z-Score
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| BOGER JOSHUA S | director 10% owner | Buy | 955,414 | $3.0M | Jun 11, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-58.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for CRVO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 13:11:54 | $1.79 | 10,395 | $$19K | BUY |
| 13:06:01 | $1.79 | 3,500 | $$6K | SELL |
| 12:59:51 | $1.78 | 6,527 | $$12K | BUY |
| 12:21:27 | $1.70 | 1,000 | $$2K | SELL |
| 12:20:29 | $1.71 | 1,000 | $$2K | SELL |
5 dark pool trades shown · $$40K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for CervoMed Inc. (CRVO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CervoMed Inc. (CRVO) is at $1.77, up 29.20% (+$0.40) at the Nov 11, 2026 close.
Latest CRVO news — Nov 7, 2026: CervoMed Inc. Posts Third-Quarter 2026 Results, Updates Cash Position
CervoMed shares fell 8.73% today, closing at $2.51 after opening at $2.75 and trading as low as $2.42 on volume of 745,656. The decline followed the company's announcement of initial Phase 2a data showing that 12 weeks of neflamapimod treatment reduced mean plasma levels of neurofilament light chain, a biomarker of neurodegeneration, in patients with nonfluent variant primary progressive aphasia.
Analyst ratings for CRVO: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
CRVO last reported on Nov 6, 2026: EPS -$0.39 vs -$0.49 expected — a beat of 20.4%.
CRVO does not currently pay a dividend.
Support: $1.27. Resistance: $1.80, $2.13, $2.40.
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
Nov 7, 2026: CervoMed Inc. Posts Third-Quarter 2026 Results, Updates Cash Position